Opinion|Videos|July 29, 2024
Clinical Considerations and Subsequent Therapies or Sequencing in HER2-Low/HER2+ mBC
Focusing on the selection of subsequent therapies for patients with HER2-low/HER2+ metastatic breast cancer, the panel discusses treatment sequencing considerations and practices.
Advertisement
Episodes in this series
Video content above is prompted by the following question:
- What has been your practice patterns and experience in sequencing ADCs for metastatic HER2-low and HER2+ mBC?
Advertisement
Related to this article
The FDA approved Orca-T, issued a CRL to a NET imaging agent, and more.
Breast oncologists weigh the future role of radiographic progression vs liquid biopsy in the timing of therapeutic shifts in metastatic breast cancer.
Drs Nunnery and Iyengar discuss FAQs about the metabolic effects of breast cancer therapy and the expanding role of GLP-1 receptor agonists in oncology.
In a recent OncLive Peer Exchange, expert investigators discussed the utility of ctDNA and MRD testing in solid tumors.
The European Union approved trastuzumab deruxtecan for previously treated, HER2-postive metastatic solid tumors.
The top 5 OncLive TV videos of the week cover insights in breast cancer, lymphoma, melanoma, prostate cancer, and ovarian cancer.
The FDA has approved new sacituzumab govitecan indications in TNBC, cleared palbociclib combination maintenance treatment in HER2-positive breast cancer, and more.
The CHMP has recommended datopotamab deruxtecan for patients with first-line metastatic TNBC who are not candidates for immunotherapy.
Advertisement
Advertisement
Trending on OncLive
1
Managing Long-Term Toxicities and Emerging Therapies in ALK-Positive NSCLC
2
The OncFive: Top Oncology Articles for the Week of 6/28
3
Five Under 5: Top Oncology Videos for the Week of 6/28
4
FDA Approves Orca-T for Matched Donor HSCT in Hematologic Malignancies
5